302 related articles for article (PubMed ID: 1658924)
21. Robot-assisted retroperitoneal lymph node dissection (RA-RPLND) in the adolescent population.
Glaser AP; Bowen DK; Lindgren BW; Meeks JJ
J Pediatr Urol; 2017 Apr; 13(2):223-224. PubMed ID: 28262537
[TBL] [Abstract][Full Text] [Related]
22. Trans- and extraperitoneal retroperitoneal lymph node dissection (RPLND) in the treatment for nonseminomatous germ cell testicular tumors (NSGCT): a single Chinese center's retrospective analysis.
Tong S; Chen M; Zu X; Li Y; He W; Lei Y; Liu W; Qi L
Int Urol Nephrol; 2014 Feb; 46(2):363-9. PubMed ID: 23996573
[TBL] [Abstract][Full Text] [Related]
23. What is the role of enlarged lymph node resection alone in patients with nonseminomatous germ cell tumor who had stage II or III disease?
Ekenel M; Keskin S; Sanli Ö; Bavbek S; Tunç M; Ander H; Ozcan F; Kiliçaslan I; Başaran M
Clin Genitourin Cancer; 2012 Sep; 10(3):185-9. PubMed ID: 22682983
[TBL] [Abstract][Full Text] [Related]
24. Primary Retroperitoneal Lymph Node Dissection for Patients With Pathologic Stage II Nonseminomatous Germ Cell Tumor-N1, N2, and N3 Disease: Is Adjuvant Chemotherapy Necessary?
Tachibana I; Kern SQ; Douglawi A; Tong Y; Mahmoud M; Masterson TA; Adra N; Foster RS; Einhorn LH; Cary C
J Clin Oncol; 2022 Nov; 40(32):3762-3769. PubMed ID: 35675585
[TBL] [Abstract][Full Text] [Related]
25. The case for observation of patients with clinical stage I nonseminomatous germ cell testicular tumors.
Swanson DA
Semin Urol; 1993 May; 11(2):92-8. PubMed ID: 7689741
[No Abstract] [Full Text] [Related]
26. Laparoscopic retroperitoneal lymph node dissection: does it still have a role in the management of clinical stage I nonseminomatous testis cancer? A European perspective.
Rassweiler JJ; Scheitlin W; Heidenreich A; Laguna MP; Janetschek G
Eur Urol; 2008 Nov; 54(5):1004-15. PubMed ID: 18722704
[TBL] [Abstract][Full Text] [Related]
27. Laparoscopic Postchemotherapy Retroperitoneal Lymph-Node Dissection Can Be a Standard Option in Defined Nonseminomatous Germ Cell Tumor Patients.
Nicolai N; Cattaneo F; Biasoni D; Catanzaro M; Torelli T; Zazzara M; Necchi A; Giannatempo P; Raggi D; Piva L; Colecchia M; Salvioni R; Stagni S
J Endourol; 2016 Oct; 30(10):1112-1119. PubMed ID: 27533924
[TBL] [Abstract][Full Text] [Related]
28. Primary chemotherapy for clinical stage II nonseminomatous germ cell tumors of the testis: a follow-up of 50 patients.
Logothetis CJ; Swanson DA; Dexeus F; Chong C; Ogden S; Ayala AG; von Eschenbach AC; Johnson DE; Samuels ML
J Clin Oncol; 1987 Jun; 5(6):906-11. PubMed ID: 2438389
[TBL] [Abstract][Full Text] [Related]
29. The indication for postchemotherapy lymph node dissection in clinical stage IS nonseminomatous germ cell tumor.
Dash A; Carver BS; Stasi J; Bajorin DF; Motzer RJ; Bosl GJ; Sheinfeld J
Cancer; 2008 Feb; 112(4):800-5. PubMed ID: 18172902
[TBL] [Abstract][Full Text] [Related]
30. Difficulties of a surveillance study omitting retroperitoneal lymphadenectomy in clinical stage I nonseminomatous germ cell tumors of the testis.
Pizzocaro G; Zanoni F; Salvioni R; Milani A; Piva L; Pilotti S
J Urol; 1987 Dec; 138(6):1393-6. PubMed ID: 2824862
[TBL] [Abstract][Full Text] [Related]
31. Retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer: impact of patient selection factors on outcome.
Stephenson AJ; Bosl GJ; Motzer RJ; Kattan MW; Stasi J; Bajorin DF; Sheinfeld J
J Clin Oncol; 2005 Apr; 23(12):2781-8. PubMed ID: 15837993
[TBL] [Abstract][Full Text] [Related]
32. Retroperitoneal lymph node dissection in patients with low stage testicular cancer with embryonal carcinoma predominance and/or lymphovascular invasion.
Stephenson AJ; Bosl GJ; Bajorin DF; Stasi J; Motzer RJ; Sheinfeld J
J Urol; 2005 Aug; 174(2):557-60; discussion 560. PubMed ID: 16006891
[TBL] [Abstract][Full Text] [Related]
33. Long-term results of laparoscopic retroperitoneal lymph-node dissection for clinical stage I nonseminomatous germ-cell testicular cancer.
Neyer M; Peschel R; Akkad T; Springer-Stöhr B; Berger A; Bartsch G; Steiner H
J Endourol; 2007 Feb; 21(2):180-3. PubMed ID: 17338618
[TBL] [Abstract][Full Text] [Related]
34. Retroperitoneal lymph node dissection in testicular cancer.
Jacobsen NE; Foster RS; Donohue JP
Surg Oncol Clin N Am; 2007 Jan; 16(1):199-220. PubMed ID: 17336244
[TBL] [Abstract][Full Text] [Related]
35. Current controversies on the role of retroperitoneal lymphadenectomy for testicular cancer.
Mano R; Di Natale R; Sheinfeld J
Urol Oncol; 2019 Mar; 37(3):209-218. PubMed ID: 30446455
[TBL] [Abstract][Full Text] [Related]
36. Minimizing treatment without compromising cure with primary surveillance for clinical stage I embryonal predominant nonseminomatous testicular cancer: a population based analysis from British Columbia.
Al-Tourah AJ; Murray N; Coppin C; Kollmannsberger C; Man A; Chi KN
J Urol; 2005 Dec; 174(6):2209-13, discussion 2213. PubMed ID: 16280765
[TBL] [Abstract][Full Text] [Related]
37. Adjuvant surgery in testicular cancer patients undergoing postchemotherapy retroperitoneal lymph node dissection.
Djaladat H; Nichols C; Daneshmand S
Ann Surg Oncol; 2012 Jul; 19(7):2388-93. PubMed ID: 22395993
[TBL] [Abstract][Full Text] [Related]
38. Primary vs. post-chemotherapy retroperitoneal lymph node dissection (RPLND) in patients with presence of teratoma at orchiectomy.
Williams SB; Kacker R; Steele GS; Richie JP
Urol Oncol; 2012; 30(1):60-3. PubMed ID: 20189842
[TBL] [Abstract][Full Text] [Related]
39. Midline Extraperitoneal Approach to Retroperitoneal Lymph Node Dissection in Testicular Cancer: Minimizing Surgical Morbidity.
Syan-Bhanvadia S; Bazargani ST; Clifford TG; Cai J; Miranda G; Daneshmand S
Eur Urol; 2017 Nov; 72(5):814-820. PubMed ID: 28325537
[TBL] [Abstract][Full Text] [Related]
40. National management trends in clinical stage IIA nonseminomatous germ cell tumor (NSGCT) and opportunities to avoid dual therapy.
Labbate CV; Werntz RP; Galansky LB; Packiam VT; Eggener SE
Urol Oncol; 2020 Aug; 38(8):687.e13-687.e18. PubMed ID: 32305267
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]